Kedrion Biopharma to commercialize RYPLAZIM® (plasminogen, human-tvmh) in U.S. to address unmet need in patients with ultra-rare condition: Plasminogen Deficiency Type 1
Retrieved on:
Wednesday, October 20, 2021
Virus, Mouth, Security (finance), Ligneous conjunctivitis, Human, Fatigue, Patient, Bleeding, Hypersensitivity, Immune system, Risk, Anticoagulant, Visual impairment, Private Securities Litigation Reform Act, Xerostomia, Collection, Gamma globulin, Headache, Macrocytic anemia, Fibrin, Abdominal pain, Acquisition, Anti-tetanus immunoglobulin, Nausea, U.S. Securities and Exchange Commission, VTE, Dizziness, FDA, Constipation, Hans Gerhard Creutzfeldt, Forward-looking statement, Plasma, Arthralgia, Pathogen, Back pain, Castelvecchio Pascoli, Anaphylaxis, Shortness of breath, Sumathi Best Television Current Reporting Award, CJD, Bloating, Degenerative disease, Goal, Thrombosis, Fetus, Research, Creutzfeldt–Jakob disease, Infection, Paroxysmal extreme pain disorder, Plasmin, Pharmaceutical industry, Medical device, Vaccine
"The most important mission at Kedrion Biopharma is to improve the lives of people with rare and serious diseases," said Kedrion Biopharma Chief Executive Officer, Val Romberg.
Key Points:
- "The most important mission at Kedrion Biopharma is to improve the lives of people with rare and serious diseases," said Kedrion Biopharma Chief Executive Officer, Val Romberg.
- RYPLAZIM meets an urgent unmet medical need for people who face plasminogen deficiency type 1, a potentially devastating, but treatable, medical condition.
- The Prometic deal also brings more cutting-edge purification technology to the Kedrion Biopharma group.
- Kedrion Biopharma is ramping up RYPLAZIM production capacity to meet patient demand and anticipates RYPLAZIM will be available in limited quantities in 2022.